• Advertise
  • Contact Us
  • About Us
  • Supplier Directory
  • SCB YouTube
  • Login
  • Subscribe
  • Logout
  • My Profile

  • CORONAVIRUS
  • LOGISTICS
    • Air Cargo
    • All Logistics
    • Express/Small Shipments
    • Facility Location Planning
    • Freight Forwarding/Customs Brokerage
    • Global Gateways
    • Global Logistics
    • Last Mile Delivery
    • Logistics Outsourcing
    • LTL/Truckload Services
    • Ocean Transportation
    • Rail & Intermodal
    • Reverse Logistics
    • Service Parts Management
    • Transportation & Distribution
  • TECHNOLOGY
    • All Technology
    • Artificial Intelligence
    • Cloud & On-Demand Systems
    • Data Management (Big Data/IoT/Blockchain)
    • ERP & Enterprise Systems
    • Forecasting & Demand Planning
    • Global Trade Management
    • Inventory Planning/ Optimization
    • Product Lifecycle Management
    • Sales & Operations Planning
    • SC Finance & Revenue Management
    • SC Planning & Optimization
    • Sourcing/Procurement/SRM
    • Supply Chain Visibility
    • Transportation Management
  • GENERAL SCM
    • Business Strategy Alignment
    • Education & Professional Development
    • Global Supply Chain Management
    • Global Trade & Economics
    • HR & Labor Management
    • Quality & Metrics
    • Regulation & Compliance
    • SC Security & Risk Mgmt
    • Supply Chains in Crisis
    • Sustainability & Corporate Social Responsibility
  • WAREHOUSING
    • All Warehouse Services
    • Conveyors & Sortation
    • Lift Trucks & AGVs
    • Order Fulfillment
    • Packaging
    • RFID, Barcode, Mobility & Voice
    • Robotics
    • Warehouse Management Systems
  • INDUSTRIES
    • Aerospace & Defense
    • Apparel
    • Automotive
    • Chemicals & Energy
    • Consumer Packaged Goods
    • E-Commerce/Omni-Channel
    • Food & Beverage
    • Healthcare
    • High-Tech/Electronics
    • Industrial Manufacturing
    • Pharmaceutical/Biotech
    • Retail
  • REGIONS
    • Asia Pacific
    • Canada
    • China
    • Europe
    • Latin America
    • Middle East/Africa
    • North America
  • THINK TANK
  • WEBINARS
    • On-Demand Webinars
    • Upcoming Webinars
  • PODCASTS
  • VIDEOS
  • WHITEPAPERS
Home » Blogs » Think Tank » COVID-19 Has Revealed Fatal Flaws in the U.S. Drug Supply Chain

Think Tank
Think Tank RSS FeedRSS

Coronavirus / Sourcing/Procurement/SRM / Global Supply Chain Management / Global Trade & Economics / Healthcare / Pharmaceutical/Biotech

COVID-19 Has Revealed Fatal Flaws in the U.S. Drug Supply Chain

June 12, 2020
Anthony Loiacono, SCB Contributor

The coronavirus pandemic has been defined in large part by shortages. Healthcare workers continue to suffer from a dearth of personal protective equipment. Hospitals have rationed ventilators, and no human can tolerate this kind of intensive support without sedation and other drugs — illuminating another problem that extends well beyond the current situation: a substantial shortage of critical pharmaceuticals in the United States. 

Driven by the pharmaceutical industry’s need to compress prices, the majority of U.S. drugs’ active pharmaceutical ingredients (APIs) are manufactured overseas. Approximately 80% of antibiotics have APIs imported from Asia, and 40% of over-the-counter drugs are sourced from China. This race to the bottom on prices was created by pharmaceutical companies making short-term contracts with manufacturers that are negotiated every six months. While this does lower prices, it also eliminates multiple manufacturers and weakens the supply chain. 

We are seeing the effects of over-reliance on offshore manufacturers today. In March, India banned the export of hydroxychloroquine. (The ban has subsequently been partially lifted following pressure from the Trump Administration.) Notwithstanding the controversy over the use of hydroxychloroquine as a treatment against COVID-19, the drug has many clinical uses including treatment for malaria and auto-immune diseases such as lupus and rheumatoid arthritis. To put this into context: There are nine manufacturers of hydroxychloroquine, and the U.S. is not one of them. As a result, pharmacies have been forced to set prescription quantity limits, and autoimmune patients have been scrambling to fill their orders.

While the COVID-19 pandemic is straining our nation’s drug supply chain, this problem dates back years. According to the U.S. Food and Drug Administration, the number of ongoing drug shortages increased from 2017 to 2018 after declining from a peak in 2011. At any given time in the U.S., there are shortages of more than 100 drugs — including those used for anesthesia, palliative care and septic shock — as well as vaccines and medical supplies like sterile water. Shortages have also been lasting longer, in some cases more than eight years, according to a 2019 report from the FDA’s Drug Shortage Task Force. Sixty-two percent of the pharmaceuticals analyzed went into shortage after supply disruptions related to manufacturing or quality problems. 

We cannot continue to put the health of our population at risk based on the policies of other countries. We must instead prevent drug shortages and enhance our own pharmaceutical manufacturing infrastructure — especially for priority APIs and excipients, as well as critical generic medication. We have the capacity and a large unemployed workforce that could fill the quality manufacturing jobs made available if we bring them back to the U.S.

Pharmaceutical shortages affect patient care by causing medication errors, compromising or delaying medical procedures, and requiring replacement of first-line therapies with alternative medications. In addition, medication shortages disproportionately impact disadvantaged populations, further exacerbating care disparities. By fortifying our own pharmaceutical supply-chain infrastructure, we can produce critical APIs and excipients year round, keep the market free of unnecessary regulation, avoid trade wars and make sure we have the ramp up capability in place when we have a crisis. This will help make us independent from a global supply chain — and allows us to negotiate from a position of strength.

Anthony Loiacono is CEO of Capital Rx, a pharmacy benefit manager.

RELATED CONTENT

RELATED VIDEOS

Wake up to live
“Supply Chains in Crisis”
updates and the latest Supply Chain News!

Subscribe to our Daily Newsletter

Timely, incisive articles delivered directly to your inbox.

Popular Stories

  • 0620_NFT.png

    Can NFTs Be an Effective Tool for Supply Chain Visibility?

    Technology
  • The Craft Beer Boom: How to Satisfy Changing Consumer Tastes

    Shortages of Beer, Popcorn Join Supply Chain Crisis

    Global Supply Chain Management
  • FedEx

    FedEx Faces Big Changes as New Boss Confronts Higher Costs, Angry Contractors

    Last Mile Delivery
  • 0621_Burrito.png

    Chipotle Zeroes in on Supply Chain Traceability and Visibility

    Sourcing/Procurement/SRM
  • cyber crime

    The Cyber Blind Spot That Makes Every Supply Chain Vulnerable

    Regulation & Compliance

Digital Edition

Scb may 2022 sm

2022 Supply Chain ESG Guide

VIEW THE LATEST ISSUE

Case Studies

  • 3PL Doubles Productivity With Robots to Fulfill Medical Supply Orders

  • E-Commerce Company Cuts Order Fulfillment Time by 40%

  • Fashion Retailer Halves Fulfillment Time With Omichannel Automation

  • Distributor Scales Business by Integrating Warehouse Automaton Software

  • Fast-Growing Fashion Brand Scales E-Commerce Fulfillment With Whiplash

Visit Our Sponsors

Yang Ming Alithya Barcoding
Blue Yonder BNSF Logistics Generix
GEP GreyOrange Here
Honeywell Intelligrated IFM Inmar
Keelvar Kinaxis Korber
Liberty SBF Locus Robotics Logility
Lucas Systems Nvidia Old Dominion
ORTEC Parsyl QIMA
Redwood Logistics Saddle Creek Logistics Schneider Dedicated
Setlog Holding AG Ship4WD Shipwell
Tecsys TGW Systems Thomson Reuters
Tive Trailer Bridge Vecna Robotics
Verity
  • More From SCB
    • Featured Content
    • Video Library
    • Think Tank Blog
    • SupplyChainBrain Podcast
    • Whitepapers
    • On-Demand Webinars
    • Upcoming Webinars
  • Digital Offerings
    • Digital Issue
    • Subscribe
    • Manage Your Subscription
    • Newsletters
  • Resources
    • Events Calendar
    • SCB's Great Supply Chain Partners
    • Supplier Directory
    • Case Study Showcase
    • Supply Chain Innovation Awards
    • 100 Great Partners Form
  • SCB Corporate
    • Advertise on SCB.COM
    • About Us
    • Privacy Policy
    • Contact Us
    • Data Sharing Opt-Out

All content copyright ©2022 Keller International Publishing Corp All rights reserved. No reproduction, transmission or display is permitted without the written permissions of Keller International Publishing Corp

Design, CMS, Hosting & Web Development :: ePublishing